Who will Benefit
EasyCheck 360™ is recommended for all men and women above the age of 35 years who have no direct symptoms of cancer and who have no personal history of cancer.
About EasyCheck 360
Early detection of cancer is critical for successful treatment and cure. Late detection invariably results in poor prognosis, very toxic drugs and high financial costs. The combining of cancer screening and other functional tests ensures ‘One Prick – Annual Screening’ to de-risk against potentially life threatening diseases in good time.
EasyCheck 360™ is a powerful combination of tests which for the first time incorporate non-invasive detection of 16 cancers and other critical blood markers for a 360º evaluation of health of individuals above the age of 35 years.
How it works
EasyCheck 360™ cancer screening is based upon breakthrough technology for detection of Circulating Tumor Cells (CTCs) which are released in the blood by malignant tumors. CTCs are very rare (about 1 to 100 CTCs per 100 – 150 million normal cells in the blood). The technology has been clinically proven through CTRI (government) registered clinical trials with over 40,000 samples from 22,000 healthy individuals and 18,000 cancer patients. The other blood tests (liver, kidney, thyroid etc.) are performed at the Thyrocare Laboratory which is one of the largest and most proficient pathology labs not only in India but worldwide.
Options
EasyCheck 360™ is available in two options:
- EasyCheck 360™ to detect up to 16 cancers and costs ₹5,999.
- Enhanced Package which covers 101 tests including 16 cancers and costs ₹8,999.
SCREENING FOR 16 CANCERS
Turn Around Time
Report will be made available within 10 days from the time the sample reaches the central laboratory.
SPECIMEN REQUIREMENTS
CANCER SCREENING
Thus, total 2 tubes containing 7 ml whole blood.
✓Note :
- Sequence of draw should not be altered.
- Blood should be drawn only and only as per above method.
- Blood drawn should be performed only by qualified phlebotomist under medical supervision.
VALIDATION
EasyCheck 360™ non-invasive diagnostic biopsy for solid organ cancers has been developed by Datar Cancer Genetics based on the findings of two clinical trials registered with the CTRI (Registration No. CTRI/2019/01/017219 and CTRI/2019/03/017918).
EasyCheck 360™ has been extensively validated with data from more than 22,000 samples from asymptomatic individual donors who underwent currently used screening tests such as LDCT, Mammography, PAP Smear, Serum CA Markers and clinical examinations, as well as more than 18,000 samples from cancer patients / patients with benign conditions totalling more than 40,000 evaluable samples till December, 2019.
EVALUTED SAMPLES (PATIENTS)
| Cancer Type | Patients |
|---|---|
| Breast | 3967 |
| Head and Neck | 3552 |
| Lung | 1378 |
| Colorectal | 1341 |
| Prostate | 1196 |
| Cervix | 930 |
| Ovary | 855 |
| Esophagus | 507 |
| Sarcoma | 440 |
| Stomach | 392 |
| Uterus + Endometrium | 365 |
| Pancreas | 385 |
| Liver | 381 |
| CNS | 349 |
| Kidney | 342 |
| Bladder | 249 |
| Bone | 220 |
| Gallbladder | 196 |
| Thyroid | 175 |
| Testes | 135 |
| Skin | 115 |
| Melanoma | 86 |
| Penis | 72 |
| Neuroendocrine | 51 |
| Others | 154 |
| Total | 17,833 |
SUMMARY
| Particulars | Samples |
|---|---|
| All Cancers | 17,833 |
| Benign Conditions | 488 |
| Asymptomatic Individuals | 22,030 |
| Total | 40,351 |
BASIS
- Tumors release thousands of cells into the circulation, where circulating tumor cells (CTCs) survive for about 1–2.5 hours.
- In order to detach from the primary tumor and disseminate into the blood, cells must undergo a cellular process known as Epithelial-Mesenchymal Transition (EMT).
- EMT enhances migratory capabilities of tumor cells, which allows cells to penetrate into the vasculature and circulate as single or clusters of circulating tumor cells (CTCs).
- CTCs extravasate having undergone the reverse process known as Mesenchymal to Epithelial Transition (MET) and colonize at distant organs.
- Circulating Tumor Cells (CTCs) are defined as EpCAM (+), PanCK (+), CD45 (-) cells. Circulating Tumor Associated Cells (C-TACs) are EpCAM(+), PanCK(+), CD45(+/-) cells of tumorigenic origin, in peripheral blood.
- Non-tumorigenic cells in peripheral blood have functional apoptotic mechanism, but CTC and C-TACs are resistant to apoptosis.
- An epigenetically active stabilizing process can eliminate normal cells and confer survival privilege on apoptosis – resistant C-TACs, CTC and C-TACs.
- Sufficient C-TACs can be enriched and harvested for Immunocytochemistry (ICC) profiling with markers used in immunohistochemistry (IHC) which aid in determination of histopathological subtypes of tumor tissue.
- Antibody clones used in the trublood® assay for analysis of tumor antigens/markers are internationally approved for IVD use.
FREQUENTLY ASKED QUESTIONS
What is Easycheck™?
Easycheck™ is a blood-based cancer screening test that involves detection of circulating tumor cells as an indication of presence of epithelial malignancy. Easycheck™ provides an advantage of providing sensitive and non-invasive screening of multiple cancers at one go in a single blood draw.
Who can avail Easycheck™?
What will the test inform?
Can I forgo rest of cancer screening modalities like mammography if I do Easycheck™?
What does negative test results mean?
How frequently can Easycheck™ be repeated?
What does an ‘Malignant Activity Detected’ test result mean?
When will the report be ready?
What will the report say?
If test result is ‘Malignant Activity Detected’, will the report also inform about likely organ of origin to undertake biopsy or specific imaging?
If organ of origin information is not provided, how will the doctor determine which investigation to undertake?
Is this test a confirmation of cancer in the body?
Does DCGL have any test for identification of organ of origin in Easycheck™ “Malignant Activity Detected’ individuals?
Can patient undergo surgery/Invasive procedures based on one or two consecutive ‘Malignant Activity Detected’ results?
Do you have data on prospective studies?
What is the time for cancer to appear on other modalities after a ‘Malignant Activity Detected’ Easycheck™ report?
What is the validation you have for this test?
Cancer Screening
Available through our facilitation partner
Available through our facilitation partner
